{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-092712","form_type":"8-K","ticker":"PSNL","cik":"0001527753","company_name":"Personalis, Inc.","filed_at":"2024-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.391694+00:00","generated_at":"2026-05-31T11:43:33.194373+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Personalis Q2 revenue $22.6M (+35% YoY); raises FY 2024 revenue guidance to $79-81M","bullets":["Total revenue $22.6M, up 35% YoY; pharma testing $13.2M (+117% YoY).","Net loss $12.8M, improved from $24.0M loss in Q2 2023; cash $87.0M.","FY 2024 revenue guidance raised to $79-81M from $76-78M; non-GAAP net loss ~$75M.","Cross-license agreement with Myriad Genetics; settled IP lawsuit with Foresight Diagnostics.","Delivered 561 molecular tests in Q2, up 66% QoQ; launched NeXT Personal Dx with Tempus AI."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-092712","json":"https://secwatch.observer/filing/0000950170-24-092712.json","markdown":"https://secwatch.observer/filing/0000950170-24-092712.md","text":"https://secwatch.observer/filing/0000950170-24-092712.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527753/000095017024092712/0000950170-24-092712-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527753/000095017024092712/psnl-20240807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:43:33.194373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}